Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Alba Llop‐Guevara, Sibylle Loibl, Guillermo Villacampa, Valentina Vladimirova, Andreas Schneeweiß, Thomas Karn, D-M. Zahm, Andrea Herencia-Ropero, Paul Jank, Marion van Mackelenbergh, Peter A. Fasching, Frederik Marmé, Elmar Stickeler, Christian Schem, Rodrigo Dienstmann, Stefan Florian, Valentina Nekljudova, Judith Balmañà, E. Hahnen, Carsten Denkert, Violeta Serra